Rocket Pharmaceuticals, Inc. (RCKT)
3.665
-0.12
(-3.04%)
USD |
NASDAQ |
Aug 26, 16:00
3.665
0.00 (0.00%)
After-Hours: 20:00
Rocket Pharmaceuticals Debt to Equity Ratio : 0.0672 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.0672 |
| March 31, 2026 | 0.104 |
| December 31, 2025 | 0.0897 |
| September 30, 2025 | 0.0798 |
| June 30, 2025 | 0.0711 |
| March 31, 2025 | 0.0615 |
| December 31, 2024 | 0.055 |
| September 30, 2024 | 0.0778 |
| June 30, 2024 | 0.0671 |
| March 31, 2024 | 0.0588 |
| December 31, 2023 | 0.0508 |
| September 30, 2023 | 0.0465 |
| June 30, 2023 | 0.063 |
| March 31, 2023 | 0.0553 |
| December 31, 2022 | 0.0467 |
| September 30, 2022 | 0.0601 |
| June 30, 2022 | 0.0574 |
| March 31, 2022 | 0.0537 |
| December 31, 2021 | 0.0497 |
| September 30, 2021 | 0.0463 |
| June 30, 2021 | 0.0566 |
| March 31, 2021 | 0.1317 |
| December 31, 2020 | 0.1225 |
| September 30, 2020 | 0.2845 |
| June 30, 2020 | 0.2562 |
| Date | Value |
|---|---|
| March 31, 2020 | 0.2372 |
| December 31, 2019 | 0.1544 |
| September 30, 2019 | 0.2015 |
| June 30, 2019 | 0.1852 |
| March 31, 2019 | 0.2561 |
| December 31, 2018 | 0.2136 |
| September 30, 2018 | 0.2829 |
| June 30, 2018 | 0.2536 |
| March 31, 2018 | 0.2297 |
| December 31, 2017 | 0.00 |
| September 30, 2017 | 0.967 |
| June 30, 2017 | 0.8559 |
| March 31, 2017 | 0.7761 |
| December 31, 2016 | 0.6691 |
| September 30, 2016 | 0.574 |
| June 30, 2016 | 0.00 |
| March 31, 2016 | 0.00 |
| December 31, 2015 | 0.00 |
| September 30, 2015 | 0.00 |
| June 30, 2015 | 0.5515 |
| March 31, 2015 | 0.5624 |
| December 31, 2014 | -1.604 |
| September 30, 2014 | -2.404 |
| June 30, 2014 | |
| March 31, 2014 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 2.956 |
| Oncolytics Biotech, Inc. | -0.0726 |
| Sangamo Therapeutics, Inc. | -1.020 |
| Sarepta Therapeutics, Inc. | 0.6845 |
| Anixa Biosciences, Inc. | 0.0127 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 423.10M |
| Total Liabilities (Quarterly) | 54.27M |
| Shareholders Equity (Quarterly) | 368.83M |
| Current Ratio | 9.245 |
| Net Debt Paydown Yield | 0.03% |